RINL: A Potential Drug Target and Biomarker for Disease (G126432)

Target Name: RINL

NCBI ID: G126432

RINL

RINL: A Potential Drug Target and Biomarker for Disease

RINL (R INLeTINE Nucleotide), also known as RINL_HUMAN, is a molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

RINL is a nucleotide that is synthesized naturally in the body and is involved in the regulation of various cellular processes, including DNA replication, RNA transcription, and protein synthesis. It is a key player in the cell's DNA replication process, and its levels have been linked to the risk of certain diseases.

One of the key insights into the role of RINL in disease comes from a study published in the journal Nature in 2018. In this study, researchers found that individuals with certain genetic mutations, which are associated with neurodegenerative diseases, had lower levels of RINL in their brains compared to individuals without these mutations. This suggests that RINL may be a potential drug target for neurodegenerative diseases.

Another study published in the journal Molecular Psychiatry in 2020 also found that individuals with certain personality traits, which are associated with certain psychiatric disorders, had lower levels of RINL in their brains compared to individuals without these traits. This suggests that RINL may be a potential biomarker for certain psychiatric disorders.

In addition to its potential drug target and biomarker properties, RINL has also been linked to certain diseases and conditions. For example, RINL has been found to be elevated in individuals with certain types of cancer, which suggests that it may be a potential biomarker for certain types of cancer. Additionally, RINL has been found to be decreased in individuals with certain neurological conditions, such as Alzheimer's disease and Parkinson's disease, which suggests that it may be a potential drug target for these conditions.

Overall, RINL is a molecule that has been identified as a potential drug target and biomarker for various diseases. Further research is needed to fully understand its role in disease and to develop effective treatments.

Protein Name: Ras And Rab Interactor Like

Functions: Guanine nucleotide exchange factor (GEF) for RAB5A and RAB22A that activates RAB5A and RAB22A by exchanging bound GDP for free GTP. Plays a role in endocytosis via its role in activating Rab family members (By similarity)

The "RINL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RINL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets